The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm

Blood Research

Volumn 48, Issue 2, 2013, Pages 127-132

  Chi, Hyun Sook ^a   Park, Sang Hyuk ^a   Cho, Young Uk ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Allele; Discrimination; Janus Kinase 2; Mutation; Myeloproliferative disorders; Real time polymerase chain reaction

Indexed keywords

ALLELE; AMPLIFICATION REFRACTORY MUTATION SYSTEM ASSAY; ARTICLE; ASSAY; BLOOD; BONE MARROW; DEMOGRAPHY; DIFFERENTIAL DIAGNOSIS; GENE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; JANUS KINASE 2 GENE; MAJOR CLINICAL STUDY; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA;

EID: 84884263595     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2013.48.2.128     Document Type: Article

References (12)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
2. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
5. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
6. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.
7. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007;21:2074-5.
8. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-84.
9. Hussein K, Bock O, Theophile K, et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009;37: 1186-93. e7.
10. Buhr T, Büsche G, Choritz H, Länger F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119:152-8.
11. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 2007;79:508-15.
12. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 2012;32:385-91.